Objectives: To describe the clinical, hormonal characteristics and phenotypic distribution of women with polycystic ovary syndrome of reproductive age at Andrology and Fertility Hospital of Hanoi.
Subject and methods: A retrospective cross-sectional study was conducted on 263 patients diagnosed with polycystic ovary syndrome according to the Rotterdam 2003 criteria.
Results: The mean age of participants was 30.0 ± 3.6 years. The mean BMI was 22.5 ± 1.8 kg/m², with 39.2% classified as overweight or obese. Phenotype D was the most prevalent (55.1%), followed by phenotype A (39.6%). BMI, AMH, LH, LH/FSH ratio, testosterone levels, and AFC differed significantly among polycystic ovary syndrome phenotypes (p < 0.001). AMH levels showed a moderate positive correlation with antral follicle count (r = 0.560; p < 0.001). BMI was significantly higher in women with hyperandrogenism compared with those without hyperandrogenism (p < 0.001).
Conclusions: Most patients with polycystic ovary syndrome were aged 25-34 years, with phenotype D being predominant. BMI was associated with hyperandrogenism. AMH levels showed a positive correlation with antral follicle count, indicating the value of AMH in assessing ovarian reserve and supporting the diagnosis of polycystic ovary syndrome.
CHARACTERISTICS OF REPRODUCTIVE-AGE WOMEN WITH POLYCYSTIC OVARY SYNDROME PRESENTING AT ANDROLOGY AND FERTILITY HOSPITAL OF HANOI
0
Views
0
Downloads
Abstract
Keywords
Polycystic ovary syndrome, polycystic ovary syndrome phenotype, hyperandrogenism, antral follicle count.
References
[1]
[1] World Health Organization. Polycystic ovary syndrome: key facts, 2023.
Google Scholar
[2]
[2] Teede H.J et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab, 2023, 108 (10):2447-2469. doi: 10.1210/clinem/dgad463.
Google Scholar
[3]
[3] Azziz R. Polycystic ovary syndrome. Obstetrics & Gynecology, 2018, 132 (2): 321-336.
Google Scholar
[4]
[4] Nelson S.M et al. Ethnic discordance in serum anti-Müllerian hormone in healthy women: a population study from China and Europe. Reprod Biomed Online, 2020, 40 (3): 461-467.
Google Scholar
[5]
[5] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 2004, 81 (1): 19-25.
Google Scholar
[6]
[6] Liu S et al. Association of antimüllerian hormone with polycystic ovarian syndrome phenotypes and pregnancy outcomes of in vitro fertilization cycles with fresh embryo transfer. BMC Pregnancy Childbirth, 2022, 22 (1): 171.
Google Scholar
[7]
[7] Đoàn Xuân Kiên, Đoàn Thị Hằng, Nguyễn Thanh Tùng. Đặc điểm kiểu hình và kết quả điều trị vô sinh của bệnh nhân hội chứng buồng trứng đa nang bằng thụ tinh trong ống nghiệm. Tạp chí Phụ Sản, 2022, 20 (1): 49-54.
Google Scholar
[8]
[8] Le M.T et al. Metabolic syndrome and insulin resistance syndrome among infertile women with polycystic ovary syndrome: a cross-sectional study from Central Vietnam. Endocrinol Metab (Seoul), 2018, 33 (4): 447-458.
Google Scholar
[9]
[9] Mansour A et al. Hyperandrogenism and anthropometric parameters in women with polycystic ovary syndrome. BMC Endocrine Disorders, 2024, 24 (1): 201.
Google Scholar
[10]
[10] Cao Ngoc Thanh et al. Defining polycystic ovary syndrome phenotype in Vietnamese women. Journal of Obstetrics and Gynaecology Research, 2019, 45 (11): 2209-2219.
Google Scholar
[11]
[11] Yong E.L et al. Polycystic ovary syndrome v. 2023: simplified diagnostic criteria for an East Asian phenotype. Ann Acad Med Singap, 2023, 52 (12): 669-678. doi: 10.47102/annals-acadmedsg.202369.
Google Scholar
[12]
[12] Azziz R et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril, 2009, 91 (2): 456-88.
Google Scholar
[13]
[13] Baba T. Polycystic ovary syndrome: criteria, phenotypes, race and ethnicity. Reprod Med Biol, 2025, 24 (1): e12630.
Google Scholar
[14]
[14] Ghafari A et al. The last update on polycystic ovary syndrome (PCOS), diagnosis criteria, and novel treatment. Endocrine and Metabolic Science, 2025, 17: 100228.
Google Scholar
[15]
[15] Wiweko B et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. Journal of Assisted Reproduction and Genetics, 2014, 31 (10): 1311-1316.
Google Scholar